Table 5.

Relative risk of VTEs before and after STS diagnosis/index date: STS versus non-cancer cohort

STS subtypea	Before odds ratio (95% CI)	After hazard ratio (95% CI)
Angiosarcoma	4.0 (1.4, 11.1)+	9.1 (2.1, 39.5)+
Fibrosarcoma	0.5 (0.1, 2.0)	1.0 (0.1, 16.0)
GIST	1.0 (0.7, 1.4)	4.0 (2.8, 5.7)+
Leiomyosarcoma	1.5 (0.6, 3.5)	5.5 (2.1, 15.0)+
Liposarcoma	Not estimable	2.5 (0.9, 7.6)
MFHb	1.4 (0.6, 3.3)	19.7 (3.7, 106.0)+
NSTc	2.1 (0.8, 5.4)	4.4 (1.1, 17.5)+
Sarcoma NOSd	1.9 (1.4, 2.6)+	5.2 (3.8, 6.9)+

All models adjusted for age at index/diagnosis date. Estimates represent the relative risk of VTE event in the 12 months before or after diagnosis/index date. STS patients 3,840; non-cancer patients = 3,480. VTE Venous Thromboembolic Event (including deep vein thrombosis,pulmonary embolism, and other thromboembolic events). OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.

^aHazard ratios for STS subtypes other than those listed were not estimable due to small numbers.

^bMaligant fibrous histiocytoma.

^cNerve sheath tumor.

^dSarcoma not otherwise specified.

⁺Statistically significant.